Author details

Full Name

Jonathan A Kelber

Affiliation

ORCID

Career Start Year

2006

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37090582	Fibronectin, DHPS and SLC3A2 Signaling Cooperate to Control Tumor Spheroid Growth, Subcellular eIF5A1/2 Distribution and CDK4/6 Inhibitor Resistance.		2023
35739142	Fibrillin-1 mutant mouse captures defining features of human primary open glaucoma including anomalous aqueous humor TGF beta-2.	Scientific Reports	2022
34239043	A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers.	Oncogene	2021
32103065	Cell surface GRP78 promotes stemness in normal and neoplastic cells.	Sci Rep	2020
31105883	Secretomes from metastatic breast cancer cells, enriched for a prognostically unfavorable LCN2 axis, induce anti-inflammatory MSC actions and a tumor-supportive premetastatic lung.	Oncotarget	2019
31558321	DHPS-dependent hypusination of eIF5A1/2 is necessary for TGFÎ²/fibronectin-induced breast cancer metastasis and associates with prognostically unfavorable genomic alterations in TP53.	Biochemical and Biophysical Research Communications	2019
30579599	Identification of myosin II as a cripto binding protein and regulator of cripto function in stem cells and tissue regeneration.	Biochemical and Biophysical Research Communications	2019
27602776	A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts.	Oncotarget	2017
28855593	ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.	Scientific Reports	2017
28381547	eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.	Cancer Res	2017
28394345	CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.	Oncogene	2017
29430386	Tumor microenvironment heterogeneity: challenges and opportunities.		2017
26868366	Cellular and molecular aspects of pancreatic cancer.	Acta Histochemica	2016
29392163	Ascending the PEAK1 toward targeting TGFÎ² during cancer progression: Recent advances and future perspectives.		2016
26297948	Identification of a PEAK1/ZEB1 signaling axis during TGFÎ²/fibronectin-induced EMT in breast cancer.	Biochemical and Biophysical Research Communications	2015
26267863	PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGFÎ² Responses in Breast Cancer.	PLoS ONE	2015
24749068	CRIPTO/GRP78 signaling maintains fetal and adult mammary stem cells ex vivo.	Stem Cell Reports	2014
25261239	A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer.	Cancer Res	2014
24161902	Procedures for the biochemical enrichment and proteomic analysis of the cytoskeletome.	Analytical Biochemistry	2014
23321642	Role of connexins in metastatic breast cancer and melanoma brain colonization.	J Cell Sci	2013
23868590	Proteomic and biochemical methods to study the cytoskeletome.	Methods in Molecular Biology	2013
22589274	KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer.	Cancer Res	2012
22809641	Cancer cell migration within 3D layer-by-layer microfabricated photocrosslinked PEG scaffolds with tunable stiffness.	Biomaterials	2012
22073163	Designer TGFÎ² superfamily ligands with diversified functionality.	PLoS One	2011
20530574	Visualizing extravasation dynamics of metastatic tumor cells.	J Cell Sci	2010
21301050	PEAK1, a novel kinase target in the fight against cancer.	Oncotarget	2010
20534451	Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected].	Proc Natl Acad Sci U S A	2010
19421146	Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways.	Oncogene	2009
18089557	Cripto is a noncompetitive activin antagonist that forms analogous signaling complexes with activin and nodal.	Journal of Biological Chemistry	2008
17991893	GRP78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth.	Molecular and Cellular Biology	2008
17030617	Cripto binds transforming growth factor beta (TGF-beta) and inhibits TGF-beta signaling.	Molecular and Cellular Biology	2006